Navigation Links
Elevated temperature enhances success of viral cancer therapy

A therapeutic approach for battling cancer that is based on infection with a specially designed virus similar to the one that causes the common cold has shown promise in clinical trials. Now, new research suggests that fever might be a useful weapon in the fight as well. The study, published in the July issue of Cancer Cell, demonstrates that tumor cells are even more sensitive to viral therapy after they have been incubated at an elevated temperature. The findings could have a significant impact on the future success of viral strategies for cancer therapy.

ONYX-015 is a mutated adenovirus that undergoes selective replication in tumor cells until the cells become so full of virus that they burst and die. The virus is modified so that it only copies itself in tumor cells and is safe for normal cells. In clinical trials, ONYX-015 was a successful therapy for many cancer patients, but the success varied considerably for reasons that were not well understood. Dr. Clodagh C. O'Shea and colleagues from the Cancer Research Institute at the University of California, San Francisco examined why ONYX-015 did not undergo replication in some cancer cells and if it might be possible to sensitize tumor cells to ONYX-015 therapy.

The researchers demonstrated that resistant tumor cells fail to complete an RNA export function that is necessary for ONYX-015 replication. Interestingly, when a cellular heat shock response was induced in the resistant tumor cells, either pharmacologically or by incubating the cells at an elevated temperature similar to that experienced by humans when they have a fever, the RNA export function was restored. Therefore, induction of the heat shock response could rescue ONYX-015 replication in resistant tumor cells.

According to Dr. O'Shea, "Our data suggest that a clinical strategy that does not advocate the use of pharmacological agents to suppress fever would favor the tumor-selective replication of ONYX-015. This study indicates th at induction of a heat shock response by pharmacological agents (that could potentially be administered systemically) or local hyperthermia, could greatly augment and broaden ONYX-015's clinical utility as a cancer therapy."

Clodagh C. O'Shea, Conrado Soria, Bridget Bagus, and Frank McCormick: "Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy" Publishing in Cancer Cell, Vol. 8, July 2005, pages 61-74 . DOI 10.1016/j.ccr.2005.06.009


Source:Cell Press

Related biology news :

1. Climate model links higher temperatures to prehistoric extinction
2. Taking evolutions temperature: Researchers pinpoint the energy it takes to make a species
3. Ocean temperature predicts spread of marine species
4. Rising ocean temperatures, pollution have oysters in hot water
5. Healthy coral reefs hit hard by warmer temperatures
6. Pulsating ultrasound enhances gene therapy for tumors
7. NYU algorithm enhances ability to detect cancer genes
8. Proteasome activator enhances survival of Huntingtons disease neuronal model cells
9. New, automated tool successfully classifies and relates proteins in unprecedented way
10. Biomarkers isolated from saliva successfully predict oral and breast cancer
11. Secret of smallpoxs success may lead to bioterror cure
Post Your Comments:

(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:3/31/2016)... , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange is ... users of its soon to be launched online site ... ) will also provide potential shareholders ... of DNA technology to an industry that is notorious ...
(Date:3/22/2016)... , March 22, 2016 ... report "Electronic Sensors Market for Consumer Industry by Type ... Others), Application (Communication & IT, Entertainment, Home ... Global Forecast to 2022", published by MarketsandMarkets, ... expected to reach USD 26.76 Billion by ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
Breaking Biology Technology: